The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils

Research in Real-Life

Status: Unknown

Conditions: Asthma

Study type: Observational

Funder types: NETWORK; Industry

Identifiers

NCT02140541

R05812

Details and patient eligibility

About

To explore the relationship between blood eosinophil counts, asthma exacerbations and patient asthma control using a large primary care based research database

Full description

Sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled corticosteroid (ICS) responsivenesss. Managing asthma based on sputum eosinophils leads to fewer exacerbations than management adhering to Global Initiative for Asthma (GINA) guidelines. However the use of sputum to measure eosinophil levels is expensive and impractical within a clinical setting. This study explores the use of blood-eosinophil levels as a clinical predictor for exacerbations and asthma control within a UK primary care dataset.

Enrollment: 130,248 patients

Sex: All

Ages: 12 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient aged 12-80 at date of last eosinophil count
• Asthma diagnosis at any time
• Blood Eosinophil reading in patient record (numeric count expressed in µl) at least one year prior to last data extraction
• Two years of continuous data

Exclusion criteria

• Any other chronic respiratory diseases
• Eosinophil counts >5000/µl (outliers)

Trial design

130,248 participants in 2 patient groups

Blood eosinophil count ≤ 400/µl

Blood eosinophil count > 400/µl